ENTRY       D09594            Mixture   Drug
NAME        Olmesartan medoxomil and azelnidipine;
            Rezaltas (TN)
COMPONENT   Olmesartan medoxomil [DR:D01204], Azelnidipine [DR:D01145]
CLASS       Cardiovascular agent
             DG01925  Renin-angiotensin system inhibitor
             DG03231  Antihypertensive
            Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
REMARK      Therapeutic category: 2149
            Product: D09594<JP>
EFFICACY    Antihypertensive
COMMENT     Azelnidipine is primarily metabolized by CYP3A4.
METABOLISM  Enzyme: CYP3A4 [HSA:1576]
INTERACTION  
BRITE       Therapeutic category of drugs in Japan [BR:br08301]
             2  Agents affecting individual organs
              21  Cardiovascular agents
               214  Antihypertensives
                2149  Others
                 D09594  Olmesartan medoxomil and azelnidipine
            Drug groups [BR:br08330]
             Cardiovascular agent
              DG01925  Renin-angiotensin system inhibitor
               D09594  Olmesartan medoxomil and azelnidipine
              DG03231  Antihypertensive
               D09594  Olmesartan medoxomil and azelnidipine
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                D09594  Olmesartan medoxomil and azelnidipine
            Drug classes [BR:br08332]
             Cardiovascular agent
              DG03231  Antihypertensive
               D09594  Olmesartan medoxomil and azelnidipine
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D09594
DBLINKS     PubChem: 124490334
///
